IMPROVEMENT OF A PROMISING MAP FOR OVARIAN CANCER

Award Information
Agency:
Department of Health and Human Services
Amount:
$149,875.00
Program:
SBIR
Contract:
N43CO0800045
Solitcitation Year:
2008
Solicitation Number:
N/A
Branch:
N/A
Award Year:
2008
Phase:
Phase I
Agency Tracking Number:
N43CO0800045
Solicitation Topic Code:
N/A
Small Business Information
RULES-BASED MEDICINE, INC.
RULES-BASED MEDICINE, INC., 3300 DUVAL RD, AUSTIN, TX, 78759
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
114417327
Principal Investigator
 Laurie Stephen
 () -
Business Contact
Phone: (512) 835-8026
Email: rlmcdade@rulesbasedmedicine.com
Research Institution
N/A
Abstract
Mortality from ovarian cancer (OvCa), the deadliest gynecological cancer in the United States has declined little for -50 years. When treated early, the 5-year survival rate is 93%, but only 19% are detected at stage I. Early-detection remains a critical, unmet medical need. Single diagnostic markers for OvCa have not been identified, although multivariate assays do offer promise. Common proteomic technologies lack ability to quantify multiple biomarkers simultaneously. Newer technologies lack sensitivity, precision and automation. Rules-Based Medicine (RBM) resolved these limitations by developing bead-based, multiplexed immunoassays for identifying disease-specific Multi-Analyte Profiles (MAPs). Combining MAPs and pattern recognition algorithms, Correlogic and RBM are developing an informational test to be used in conjunction with existing tests and observations, to screen high-risk women facing surgery for suspicion of OvCa. A preliminary multi-variate test with 95% sensitivity overall (88% stage I

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government